Authors: Diener, Hans-Christoph¹; Evers, Stefan²

Source: Clinical Drug Investigation, Volume 27, Number 1, 2007 , pp. 59-66(8)

Publisher: Adis International

Abstract:

Objective: Addressing the needs of migraineurs by actively seeking patient feedback on disease-related disability and treatment satisfaction may lead to improved management and treatment outcomes. Patient feedback can be collected in postmarketing surveillance (PMS) studies. The objective of this PMS study was to evaluate the efficacy and tolerability of zolmitriptan 5mg nasal spray in the acute treatment of migraine attacks.

Patients and methods: Patients received zolmitriptan 5mg nasal spray to treat migraine attacks of any severity and were followed up after a maximum of 4 months. Patients evaluated the efficacy and tolerability of zolmitriptan nasal spray, and were asked whether they wished to continue using zolmitriptan nasal spray and their preference compared with previous treatments. Physicians also assessed the efficacy and tolerability of zolmitriptan nasal spray.

Results: A total of 1838 patients (84.8% females) participated in the study. Within 30 minutes of administration of zolmitriptan nasal spray, 85.0% of patients reported improvements in headache pain, with 25.1% reporting an improvement within 10 minutes. At 1 hour post-dose, 57.9% of patients were pain free and 61.7% were able to resume usual daily activities. Most patients (72.9%) rated zolmitriptan nasal spray as `better' than previous therapy. The majority (88.8%) expressed a wish to continue using zolmitriptan nasal spray. Physicians evaluated the efficacy of zolmitriptan nasal spray as `excellent' or `good' in 89.4% of patients. Tolerability was evaluated as `excellent' or `good' in 91.6% of patients.

Conclusions: Zolmitriptan 5mg nasal spray provides favourable efficacy and tolerability in the acute treatment of migraine attacks. Most patients assessed zolmitriptan nasal spray as `better' than previous treatment, with nearly all wishing to continue using it.

Keywords: Migraine; Pain; Patient preference; Zolmitriptan

Document Type: Research article

Affiliations: 1: 1 Department of Neurology, University of Duisburg-Essen, Essen, Germany 2: 2 Department of Neurology, University of Münster, Münster, Germany

Publication date: 2007-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Diener, Hans-Christoph ;  Evers, Stefan

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers